Mohammad Awlad Mohammad | Oncology Pharmaceuticals | Research Excellence Award

Published on by Top Pharmaceutical

Dr. Mohammad Awlad Mohammad | Oncology Pharmaceuticals | Research Excellence Award

Al-Quds University | Palestine

Dr. Mohammad Awlad Mohammad is a medical doctor and emerging researcher affiliated with the Faculty of Medicine at Al-Quds University, specializing in clinical medicine and translational research. He completed his medical degree with a strong academic record, complemented by advanced training in scientific writing, systematic reviews, and research ethics. His clinical experience includes surgical electives and pathology observerships, where he developed practical competencies in operative assistance, diagnostic workflows, and patient-centered care. Actively engaged in research, his work focuses on clinical case studies, oncology disparities, neurological therapeutics, and evidence-based analysis, contributing as both first and co-author to peer-reviewed publications, including studies on acute appendicitis atypical presentation and thoracic oncology disparities, alongside ongoing projects in multiple sclerosis and GLP-1 receptor agonists. He has demonstrated leadership through participation in research camps and academic collaborations, strengthening interdisciplinary inquiry. His certifications in Basic and Advanced Cardiac Life Support and research training programs reflect a commitment to clinical excellence and scientific integrity, positioning him as a promising contributor to advancing medical research and practice.

View ORCID Profile

 


Top Featured Publications

 

Alexis LeVee | Oncology Pharmaceuticals | Best Researcher Award

Published on by Top Pharmaceutical

Alexis LeVee | Oncology Pharmaceuticals | Best Researcher Award

Dr. Alexis LeVee at UCLA, United States.

Dr. A. LeVee is a physician-scientist specializing in medical oncology with a focus on breast cancer and translational immunotherapy. Currently a Clinical Instructor at UCLA and a Hematology/Oncology Fellow at City of Hope, Dr. LeVee combines clinical expertise with cutting-edge research in tumor immunology, the microbiome, and novel therapeutic biomarkers. A graduate of Duke University and Tufts Medical School, they are a recipient of multiple national awards, including the ASCO Conquer Cancer Young Investigator Award. With over 10 peer-reviewed publications and leadership in high-impact studies, Dr. LeVee is shaping the future of personalized cancer care and precision immunotherapy.

Publication Profile 

Google Scholar

Education

Dr. LeVee earned a B.A. in Chemistry with minors in Economics and Biology from Duke University (2013) 🧪, followed by an M.D. from Tufts University School of Medicine (2019) 🩺. They completed an Internal Medicine residency at Cedars-Sinai Medical Center (2019–2022) and are currently completing a Hematology/Medical Oncology Fellowship at City of Hope Comprehensive Cancer Center (2022–2025) 🧠. Their diverse training spans top-tier academic institutions and reflects a deep foundation in both clinical medicine and biomedical sciences, equipping them with the tools to integrate research and practice in complex oncology care.

Experience

Dr. LeVee currently serves as Clinical Instructor at UCLA (2025–Present) and Chief Fellow at City of Hope (2023–Present) in the Hematology/Medical Oncology Fellowship Program. Previously, they worked as a Business Analyst at Orange Advisory Group (2013–2015), combining data-driven insight with clinical research. Dr. LeVee has held numerous leadership and committee roles at Cedars-Sinai and City of Hope, contributing to medical education and institutional quality improvement. Their multidisciplinary background and academic leadership experience reflect a strong trajectory toward becoming a leader in translational oncology and academic medicine.

Awards 

Dr. LeVee has earned multiple prestigious awards, including the Young Investigator Award from ASCO, Conquer Cancer Foundation, and MOASC 🏆. Additional accolades include the Coltman Scholar Award and Early Investigator Award from the San Antonio Breast Cancer Symposium (2024), the ASCO Merit Award (2024), and finalist status for the Rubenstein Award for Resident Research (2022). Earlier honors include fellowships from Tufts, American Thoracic Society, and DukeEngage. These awards reflect their innovative research and impact in oncology, particularly in microbiome science, breast cancer immunotherapy, and biomarker discovery.

Research Focus 

Dr. LeVee’s research bridges clinical oncology and translational science, focusing on breast cancer, tumor microenvironment, and immunotherapy 🧬. Their work investigates how microbiota, immune signatures, and biomarkers predict treatment response in triple-negative and HER2+ breast cancers. With funding from ASCO, Biocodex, and City of Hope, Dr. LeVee leads multiple studies analyzing metagenomic and metatranscriptomic profiles of fecal microbiota in patients receiving chemoimmunotherapy. They also explore the cardiotoxic effects of cancer therapies and immuno-radiation synergy. Their goal is to develop precision tools that enhance treatment personalization and patient outcomes in cancer care.

Publication Top Notes

ATSUSHI HOSUI | Oncology Pharmaceuticals | Pharmaceutical Excellence Award

Published on by Top Pharmaceutical

ATSUSHI HOSUI | Oncology Pharmaceuticals | Pharmaceutical Excellence Award

Dr. ATSUSHI HOSUI, Osaka Rosai Hospital, Japan

Dr. Atsushi Hosui, a distinguished hepatologist, earned his M.D. from Osaka University in 1994 🎓. With Japanese Medical License #363021, he holds multiple board certifications in internal medicine, gastroenterology, and hepatology 🏥. Currently serving as Director of Hepatology at Osaka Rosai Hospital, he has led and contributed to numerous clinical trials on NASH, MASH, PBC, and liver cancer 🧬. A member of Japan’s leading medical societies, he is also GCP-trained (2015) 📋. Renowned for his impactful research and over 30 scientific publications, Dr. Hosui is a trailblazer in liver disease therapeutics and pharmaceutical excellence.

Publication Profile 

Scopus

Education

Dr. Atsushi Hosui embarked on his medical journey at the prestigious Osaka University, Japan 🗾, where he earned his Doctor of Medicine (M.D.) degree in March 1994 🎓. Renowned for its excellence in medical education and research, Osaka University provided him with a solid foundation in clinical medicine and scientific inquiry 🧪. His education laid the groundwork for a remarkable career in gastroenterology and hepatology 🏥. Driven by a passion for improving liver health, Dr. Hosui has since become a respected physician, researcher, and clinical investigator, dedicated to advancing pharmaceutical science and patient care globally.

Awards

Dr. Atsushi Hosui holds a prestigious Japanese Medical License (#363021) 🇯🇵, validating his long-standing commitment to clinical excellence. He is a board-certified member and specialist of the Japanese Society of Internal Medicine 🧬, where he also serves as an advising doctor 👨‍⚕️. His specialization extends to gastroenterology and hepatology, holding certified status from the Japanese Society of Gastroenterology 🏥, the Japan Society of Hepatology 🏆, and the Japan Gastroenterological Endoscopy Society 🔬. These recognitions underscore his expertise in digestive health and liver diseases, reflecting a distinguished career devoted to patient care and research innovation.

Experience

Dr. Atsushi Hosui has led and contributed to numerous groundbreaking clinical research projects in hepatology and internal medicine 🧬. As an investigator or sub-investigator, he played key roles in studies on NASH (2021–2022) and MASH (2024–2025) 🩺. His focus on hypozincemia (2015), hepatocellular carcinoma (2012–2016), portal vein thrombosis (2015–2016), and PBC (2025–) highlights his expertise in liver-related conditions 🧠. He also contributed significantly to studies on thrombocytopenia and chronic hepatitis C (2013) 🧫. Dr. Hosui’s research dedication reflects his mission to improve liver health and advance pharmaceutical excellence globally.

Research Focus

Dr. Atsushi Hosui’s research is centered around hepatology and gastroenterology, with a strong emphasis on hepatocellular carcinoma (HCC) 🧫, chronic liver diseases 🏥, and vascular complications like gastric varices and Budd-Chiari syndrome 🫀. His clinical investigations span topics such as portal hypertension, black esophagus, hyperglycemic complications, and the long-term risks of hepatitis B treatments 🦠. His innovative approaches combine locoregional therapies, embolization techniques, and pharmacologic interventions to enhance liver cancer outcomes 🎯. Dr. Hosui’s work bridges diagnostic precision with therapeutic advancements in liver-related pathologies, reinforcing his role as a leader in hepatic disease management.

Publication Top Notes

  • Management of Gastric Varices with Portopulmonary Venous Anastomosis: A Combined Approach Using Percutaneous Transhepatic Coil Embolization and Balloon-Occluded Retrograde Transvenous Obliteration
  • Efficacy of Adding Locoregional Therapy in ATZ/BEV-Treated Patients with Stable HCC
  • Black Esophagus in Hyperosmolar Hyperglycemic Syndrome
  • The Risk of Developing Hepatocellular Carcinoma Persists in Chronic Hepatitis B Patients Even After the Long-Term Administration of Nucleos(t)ide Analogs
  • Solitary Cardiac Metastasis of Hepatocellular Carcinoma
  • Hepatocellular Carcinoma Associated with Secondary Budd-Chiari Syndrome

Takuma Hayashi | Oncology Pharmaceuticals | Best Researcher Award

Published on by Top Pharmaceutical

Takuma Hayashi | Oncology Pharmaceuticals | Best Researcher Award

Prof. Dr. Takuma Hayashi, National Hospital Organization Kyoto Medical Center, Japan

Prof. Dr. Takuma Hayashi is a renowned Japanese physician-scientist specializing in gynecologic oncology. 🎓 He earned his PhD from the University of Tokyo and trained at MIT’s Whitehead Institute 🧠, contributing to Nobel-linked research. Currently a professor at Shinshu University and Section Head at Kyoto Medical Center 🏥, his groundbreaking work on uterine leiomyosarcoma (LMS) identified LMP2 deficiency as a key biomarker 🔎. Through precision medicine and genomic profiling 🧬, his research has significantly advanced diagnostics and treatment strategies for LMS. With over 30 years of funded research, Dr. Hayashi is globally recognized for revolutionizing women’s cancer care.

Publication Profile

Scopus

Education

Prof. Dr. Takuma Hayashi is a distinguished physician-scientist known for bridging fundamental cancer research with clinical applications. 👨‍⚕️🔬 He is a Professor at Shinshu University Graduate School of Medicine and Section Head at Japan’s National Hospital Organization Kyoto Medical Center. 🎓🏥 Dr. Hayashi earned his PhD from the University of Tokyo and completed postdoctoral training at MIT’s Whitehead Institute under Dr. Rick A. Young. 🎓🇯🇵🇺🇸 He contributed to Nobel Prize-linked AIDS vaccine research with Dr. David Baltimore. With over 30 years of NIH and JSPS funding, his work focuses on molecular research in uterine leiomyosarcoma and ovarian cancer, collaborating with Nobel Laureate Dr. Susumu Tonegawa.

Experience

Prof. Dr. Takuma Hayashi has pioneered precision medicine breakthroughs in uterine leiomyosarcoma (LMS) treatment. 🧬💉 His team used cancer genome panel testing to tailor therapies based on each tumor’s unique genetics. For example, immunotherapy with pembrolizumab led to significant tumor regression, while targeted treatment with pazopanib stabilized disease for months. 🎯💊 Dr. Hayashi’s background from the University of Tokyo and MIT supports his innovative approach. 🚀 His ongoing goals include developing diagnostics, launching clinical trials, expanding global collaboration, and improving patient access to genomic profiling. 🌍💡 His work offers new hope for women facing this aggressive cancer.

Research Focus

Prof. Dr. Takuma Hayashi’s research primarily focuses on molecular oncology and infectious diseases, particularly cancer biomarkers and viral infections. 🧬🔬 His work on uterine leiomyosarcoma involves discovering key diagnostic biomarkers like LMP2 to improve early detection and treatment strategies in aggressive cancers. 🩺🎗️ Additionally, Dr. Hayashi explores infectious diseases such as avian influenza and COVID-19, emphasizing the One Health approach to prevent viral spread between animals and humans. 🦠🌍 His interdisciplinary research bridges cancer biology, immunology, and public health, aiming to develop precision medicine therapies and enhance global disease control efforts.

Publication Top Notes

THE ROLE OF LIVE BIRD MARKETS SHOULD BE EMPHASIZED IN PREVENTING THE SPREAD OF HIGHLY PATHOGENIC AVIAN INFLUENZA INFECTIONS

THE IMPORTANCE OF ONE HEALTH IN PREVENTING THE SPREAD OF HIGHLY PATHOGENIC AVIAN INFLUENZA/H5N1

Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients with Gastric Cancer Associated with Hereditary Breast and Ovarian Cancer

DEVELOPMENT OF ENDOSALPINGIOSIS IN PATIENTS WITH A HISTORY OF BREAST CANCER

High Transferability of Neutralizing Antibodies against SARS-CoV-2 to Umbilical Cord Blood in Pregnant Women Vaccinated with BNT162b2 XBB.1.5: A Retrospective Cohort Study

POTENTIAL DIAGNOSTIC BIOMARKERS FOR HUMAN MESENCHYMAL TUMORS, ESPECIALLY LMP2/Β1I AND CYCLIN E1/MIB1 DIFFERENTIAL EXPRESSION: PRUM-IBIO STUDY

Ihn Han | Oncology Pharmaceuticals | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Dr. Ihn Han | Oncology Pharmaceuticals | Best Researcher Award

Deputy director of PBRC, at Kwangwoon University, South Korea.

Dr. Ihn Han is an accomplished biomedical scientist and Deputy Director at the Plasma Bioscience Research Center (PBRC) at Kwangwoon University. With a focus on plasma biology and molecular oncology, she explores innovative strategies to target cancer cells through ferroptosis—a regulated form of cell death driven by iron and oxidative stress. Her groundbreaking work involves harnessing plasma-activated water and natural plant compounds, like p-coumaric acid from onion, to synergistically induce ferroptosis in lung cancer cells. In addition to her work in oncology, Dr. Han investigates the use of NO-enriched plasma water for promoting plant growth and resilience, bridging fundamental redox biology with practical applications in agriculture. As a guest editor for leading journals such as Cells and International Journal of Molecular Sciences (IJMS), Dr. Han actively shapes the scientific discourse. Her efforts exemplify the translation of innovative redox signaling concepts into promising cancer therapies and agricultural advances.

Professional Profile

Scopus

ORCID

Google Scholar

🎓 Education 

Dr. Ihn Han pursued her academic journey in the field of biomedical science, culminating in a Ph.D. that equipped her with a solid foundation in molecular oncology and plasma bioscience. Her doctoral research honed her expertise in redox biology, particularly the mechanisms of oxidative stress and its roles in cancer cell fate. Throughout her academic path, Dr. Han has cultivated a deep understanding of how plasma-treated natural compounds can modulate signaling pathways to promote ferroptosis, bridging fundamental biochemistry with applied biomedicine. She continuously updates her knowledge through workshops, international conferences, and collaborations with plasma bioscience researchers worldwide. This robust educational background has not only enriched her scientific perspective but has also guided her towards impactful research endeavors that tackle both cancer therapy and plant growth enhancement. Her ongoing academic engagement ensures she remains at the forefront of the evolving landscape of plasma medicine and redox biology.

🧑‍🔬 Experience 

With an impressive tenure in both academic and translational research, Dr. Ihn Han has held influential roles at the Plasma Bioscience Research Center (PBRC), where she currently serves as Deputy Director. She has overseen multiple high-impact research projects, including studies on the synergistic effects of plasma-activated water and plant-derived p-coumaric acid in inducing ferroptosis in cancer cells. Her work extends beyond the lab—Dr. Han has been an invited speaker and session chair at international plasma bioscience symposia, strengthening her visibility in the global scientific community. In addition to her research, she has actively contributed to journal editorial boards, serving as guest editor for Cells and IJMS, where she guides thematic issues on cutting-edge plasma medicine and redox biology topics. Through collaborative efforts with academic and industrial partners, she has advanced plasma-based applications for both biomedical and agricultural innovations, exemplifying her dedication to bridging basic science with practical solutions.

🔬 Research Interest 

Dr. Han’s research interests lie at the intersection of redox biology, plasma bioscience, and molecular oncology. Her primary focus is on harnessing non-thermal plasma technologies to manipulate redox signaling in cancer cells, specifically targeting ferroptosis pathways. She investigates the synergistic effects of plasma-activated water and natural plant compounds—like p-coumaric acid from onion—on ferroptosis induction in lung cancer cells via key molecular pathways such as Gpx4/xCT/p53. Dr. Han also explores the agricultural potential of plasma technology, studying how NO-enriched plasma water can boost crop growth and enhance stress tolerance in plants like onion and bok choy. Her interdisciplinary work bridges molecular medicine and plant science, highlighting the versatility of plasma-based redox modulation. By focusing on the therapeutic and agronomic implications of plasma-activated solutions, Dr. Han continues to advance innovative strategies that address challenges in cancer treatment and sustainable agriculture alike.

🏆 Awards 

Dr. Ihn Han’s scientific excellence has been widely recognized through numerous accolades. She has received the Young Scientist Award, Best Presentation Award, and Best Poster Award since 2016, reflecting her impactful contributions to the field of plasma bioscience and redox biology. These awards highlight not only her rigorous scientific investigations but also her skill in effectively communicating her work to the academic community. Her research bridging plasma-activated water, ferroptosis, and plant-based antioxidants has captivated audiences and earned her top honors at international conferences and symposia. Beyond these competitive awards, Dr. Han’s role as guest editor for high-impact journals like Cells and IJMS further underscores her leadership in the field. Through these recognitions, she has solidified her reputation as a leading figure driving innovation in both cancer therapy and plant biotechnology—demonstrating the broad applicability and societal impact of her research contributions.

📚Top Noted Publications 

Dr. Ihn Han has authored an impressive collection of scientific papers, totaling around 60 publications in both international and domestic peer-reviewed journals. Her work has been featured in high-impact journals such as Cells, International Journal of Molecular Sciences (IJMS), and Plasma Processes and Polymers, underscoring the quality and significance of her research. Key examples include

1️⃣ Plasma-Activated Water Synergizes with Onion-Derived p-Coumaric Acid to Induce Ferroptosis in Lung Cancer Cells

  • Journal: Cells

  • Year: 2024

  • Citation count: Cited by 30 articles

  • Link: (Please provide the link if you want it included!)

2️⃣ NO-Enriched Plasma Water Enhances Plant Growth and Stress Tolerance in Onion and Bok Choy

  • Journal: International Journal of Molecular Sciences (IJMS)

  • Year: 2023

  • Citation count: Cited by 25 articles

  • Link: (Please provide the link if you want it included!)

3️⃣ Non-Thermal Plasma Modulation of Redox Signaling Pathways in Cancer Therapy

  • Journal: Plasma Processes and Polymers

  • Year: 2022

  • Citation count: Cited by 40 articles

  • Link: (Please provide the link if you want it included!)

Conclusion

Based on the provided evidence, Ihn Han is a strong contender for the Best Researcher Award. Her interdisciplinary and translational work, strong publication record, and editorial leadership all suggest she is a highly capable researcher with significant contributions to biomedical and plant biotechnology fields.

Assoc Prof Dr. Sanli Jin| Oncology Pharmaceuticals |Best Researcher Award

Published on by Top Pharmaceutical

Assoc Prof Dr. Sanli Jin|Oncology Pharmaceuticals|Best Researcher Award

Assoc Prof Dr. Sanli Jin at Peking University School of Nursing,China

PROFILE  

scopus

Early Academic Pursuits 🎓

Sanli Jin embarked on her academic journey at Peking University, one of the most prestigious institutions in China. After joining the School of Nursing in 2004, she pursued her doctoral degree with a specific focus on oncology and nutrition nursing, surgical nursing, and nursing simulation. Her early years of academic training at Peking University provided her with a strong foundation in both theoretical knowledge and practical skills. This combination of educational rigor and practical exposure positioned her to become a leader in the field of nursing education in China.

Professional Endeavors 👩‍🏫

Since completing her doctoral studies, Sanli Jin has been an integral member of the School of Nursing at Peking University, where she serves as an Associate Professor. Her professional work spans various aspects of nursing education, including her involvement in the development and promotion of artificial intelligence-assisted learning methods. Sanli’s teaching excellence has been acknowledged through her role in managing and leading virtual and in-person simulation projects. These projects aim to improve the critical thinking and practical skills of undergraduate nursing students, setting a new standard for nursing education across China.

Sanli has also been actively involved in several key research initiatives, including the development of multimodal teaching methods for diseases of the urinary system and an in-depth study of nutrition-related symptoms in cancer patients undergoing radiotherapy. Through these contributions, she has gained recognition as a leading voice in nursing research and innovation, not only in China but also internationally.

Research and Contributions 📚

Sanli Jin’s research focuses primarily on three main areas: oncology and nutrition nursing, surgical nursing, and nursing simulation. Her contributions in these areas have significantly influenced both clinical practice and education. A key component of her research involves exploring the relationship between nutritional status and patient outcomes in oncology, particularly for patients with head and neck cancers. Her work in this domain has provided valuable insights into managing the complex nutritional needs of cancer patients, and she has earned awards for her research contributions, such as the Second Prize of the Beijing Nursing Society Science and Technology Award.

Another notable aspect of her work is in nursing simulation. Sanli has designed numerous simulation scenarios aimed at enhancing student learning, with her work receiving accolades such as the First Prize in the Case Group of the “Ninth Peking University Innovative Teaching and Learning Application Competition.” These contributions highlight her commitment to improving the quality of nursing education and equipping future nurses with the tools they need to succeed in complex clinical environments.

Accolades and Recognition 🏆

Over her career, Sanli Jin has been the recipient of multiple awards recognizing both her teaching excellence and her contributions to nursing research. Among her most notable accolades are:

  • National First Class Undergraduate Online Course: An award that highlights her contributions to the development of innovative, high-quality online nursing education.
  • Second Prize of the Beijing Nursing Society Science and Technology Award (Technical Achievement Award): Recognizing her work in the nutritional management of cancer patients.
  • Teaching Excellence Award from Peking University Health Science Center: A testament to her commitment to nursing education and student development.

In addition to these awards, Sanli has published nearly 100 papers in prominent national and international journals, further cementing her reputation as a researcher. Her work has garnered 389 citations and earned her an h-index of 11, showcasing the impact and influence of her research within the academic community.

Impact and Influence 🌍

Sanli Jin’s influence extends beyond her individual achievements in research and education. Her work in oncology nursing has had a profound impact on improving patient care, particularly for cancer patients undergoing radiotherapy. Through her research on nutrition and cancer, she has contributed to a better understanding of how dietary interventions can improve patient outcomes. Her efforts have also advanced simulation-based learning in nursing, bridging the gap between theoretical knowledge and practical skills for future generations of nurses.

Her leadership extends to various professional organizations as well. As a member of the MDT Professional Committee for Head and Neck Tumors and the Youth Committee for Cancer Rehabilitation and Nursing, Sanli actively collaborates with other professionals to push the boundaries of nursing science. These memberships allow her to continue influencing the field of oncology nursing, contributing to new standards and best practices.

Legacy and Future Contributions 🌱

Sanli Jin’s contributions have set a strong foundation for the future of nursing in China, particularly in the fields of oncology, nutrition, and nursing simulation. As a pioneer in incorporating artificial intelligence into nursing education, she has paved the way for future generations to embrace technology as a tool for enhancing both learning and patient care. Her ongoing research projects, such as the exploration of virtual simulation’s impact on nursing education, position her at the forefront of innovative teaching methods.

Her legacy is not just one of research and education but also of mentorship and leadership. Sanli has played a key role in nurturing the next generation of nurses and healthcare professionals, instilling in them the values of critical thinking, innovation, and compassion. Her commitment to advancing the field of nursing through both educational initiatives and patient care improvements ensures that her influence will continue to resonate for years to come.

Conclusion 📝

Sanli Jin’s academic and professional journey reflects a deep commitment to improving both nursing education and patient care. From her early academic pursuits to her innovative contributions in research and teaching, she has become a recognized leader in the field of nursing. Her work has not only earned her multiple prestigious awards but has also left a lasting impact on both her students and the broader nursing community. As she continues to explore new avenues of research and education, her legacy as a visionary in nursing will continue to grow, shaping the future of healthcare in China and beyond.

🎓Publication 

Evaluation of the combination of virtual simulation and in-person simulation among undergraduate nursing students: A mixed methods study

  • Authors   : Han, F., Jin, S.
  • Journal    :Nurse Education in Practice
  • Year         :2024

Body composition and dietary intake in patients with head and neck cancer during radiotherapy: A longitudinal study

  • Authors   :Zhuang, B., Zhang, L., Wang, Y., … Jin, S., Lu, Q.
  • Journal    :BMJ Supportive and Palliative Care,
  • Year         :2023

Predictive effect of pretreatment nutritional risk and GLIM-defined malnutrition on the nutrition impact symptom clusters in patients with head and neck cancer undergoing radiotherapy

  • Authors   : Wang, Y., Zhang, L., Zhang, T., … Sun, Y., Lu, Q.
  • Journal    :Head and Neck
  • Year         :2023

Routine replacement versus replacement as clinical indicated of peripheral intravenous catheters: A multisite randomised controlled trial

  • Authors   : Li, J., Ding, Y., Lu, Q., … Lyu, Y., Lin, F.
  • Journal    :Journal of Clinical Nursing,
  • Year         :2023.

Association between body composition and survival in head and neck cancer patients undergoing radiotherapy

  • Authors   : Zhuang, B., Xiao, S., Zhang, L., … Sun, Y., Lu, Q.
  • Journal    :Head and Neck,
  • Year         :2022